From Policy & Medicine
By Thomas Sullivan
June 22, 2019
EXCERPT
As we have previously reported, the federal government has taken an acute interest in pharmaceutical drug pricing, resulting in a raft of hearings and draft legislation. States are getting on board too, with a Maryland law to go into effect on July 1, 2019, creating a Prescription Drug Affordability Board. The Board was created by a drug pricing bill, passed by the Maryland General Assembly last spring.
The Board will consist of five members, each having expertise in health care economics or clinical medicine. The members are appointed by various elected officials, including the Maryland Governor, Speaker of the House, President of the Senate and Attorney General.
The Board will work in conjunction with a Prescription Drug Stakeholder Council, which will consist of 25 members from various stakeholder groups, including representatives of pharmacists, brand and generic biopharmaceutical manufacturers, physicians and hospitals, managed care organizations, labor unions, health care coalitions, organizations for seniors and diverse communities, and pharmacy benefit managers.
Last modified: June 22, 2019
